Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00588900
Other study ID # CALGB-80502
Secondary ID CALGB-80502CDR00
Status Terminated
Phase Phase 2
First received December 20, 2007
Last updated December 9, 2016
Start date March 2008
Est. completion date November 2011

Study information

Verified date December 2016
Source Alliance for Clinical Trials in Oncology
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving irinotecan together with cediranib may kill more tumor cells.

PURPOSE: This phase II clinical trial is studying how well giving irinotecan together with cediranib works in treating patients with metastatic colorectal cancer that did not respond to previous oxaliplatin, fluoropyrimidine, and bevacizumab.


Description:

OBJECTIVES:

Primary

- To determine the proportion of patients who are free from progression at 12 weeks from the start of second-line therapy.

Secondary

- To determine objective response rate.

- To determine overall survival.

- To further define the dosing and safety profile of irinotecan hydrochloride and cediranib.

OUTLINE: This is a multicenter study.

Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date November 2011
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically documented metastatic colorectal cancer

- The site of the primary lesion must be or have been confirmed endoscopically, surgically, or radiologically to have been in the colon or rectum

- Patients with a history of histologically proven colorectal cancer treated by surgical resection and who develop radiological or clinical evidence of metastatic cancer do not require additional histological or cytological confirmation of metastatic disease unless either of the following are true:

- An interval of greater than five years has elapsed between the primary surgery and the development of metastatic disease

- The primary cancer was stage I

- Must have measurable disease, defined as in at least one dimension (longest dimension to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral CT scan

- Lesions that are considered nonmeasurable include the following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Lymphangitis cutis/pulmonis

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- Must have received one and only one prior regimen for metastatic disease containing oxaliplatin, a fluoropyrimidine, and bevacizumab

- Patients who discontinue oxaliplatin due to toxicity are eligible provided they progressed on the fluoropyrimidine component with or without bevacizumab

- No known brain metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- ANC = 1,500/µL

- Platelet count = 100,000/µL

- Hemoglobin = 8 g/dL

- Leukocytes = 3,000/mm³

- Calculated creatinine clearance > 50 mL/min

- ALT/AST = 2.5 times upper limit of normal (ULN)

- Urine protein < 1+ protein OR protein < 1g by 24-hour urine collection and urine protein:creatinine ratio < 1.0

- Total bilirubin normal

- Not pregnant or nursing

- Negative pregnancy test

- No known end-stage liver disease or active hepatitis

- No colonic or small bowel disorders (e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis) that predispose to diarrhea in which the symptoms are uncontrolled as indicated by baseline pattern of > 3 watery or soft stools daily in patients without a colostomy or ileostomy

- Patients with a colostomy or ileostomy may be entered at investigator discretion

- History of hypertension allowed provided it is well controlled (BP < 150/90 mm Hg) on a regimen of antihypertensive therapy

- No concurrent congestive heart failure (New York Heart Association class III or IV)

- No significant history of bleeding events or gastrointestinal (GI) perforation

- Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower GI bleeding) within 3 months prior to beginning treatment are not eligible unless the source of bleeding has been surgically resected

- Patients with a history of GI perforation within 12 months prior to beginning treatment are not eligible

- No arterial thrombotic events within 6 months before beginning treatment, including any of the following:

- Transient ischemic attack

- Cerebrovascular accident

- Unstable angina or angina requiring surgical or medical intervention within the past 6 months

- Myocardial infarction

- No serious or nonhealing wound, ulcer, or bone fracture

- Patients with clinically significant peripheral artery disease (i.e., claudication on ambulating less than one block) or any other arterial thrombotic event within 6 months are also ineligible

- QTc interval = 470 msec

- No personal or family history of long QT syndrome.

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Must have recovered from all acute toxicities of prior therapy for metastatic disease except peripheral neuropathy

- At least 6 weeks between the last dose of bevacizumab and the first dose of cediranib

- Prior pelvic irradiation is allowed (as long as the measurable lesion is outside the radiotherapy field)

- Completed any major surgery = 4 weeks from start of treatment and completed any minor surgery = 1 week prior to start of treatment

- Insertion of a vascular access device is not considered major or minor surgery from the standpoint of protocol eligibility

- Patients must have fully recovered from the procedure and have a fully healed incision

- Patients on full-dose anticoagulation (e.g., warfarin) are eligible provided that both of the following criteria are met:

- The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or is on a stable dose of low molecular weight heparin

- The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

- Patients receiving anti-platelet agents are eligible

- Patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligible

- The use of agents with strong proarrhythmic potential is not permitted during the study

- Patients who received treatment on CALGB-C80405 and whose treatment failed are eligible for this study

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cediranib maleate

irinotecan hydrochloride


Locations

Country Name City State
United States Hematology Oncology Associates of the Quad Cities Bettendorf Iowa
United States Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill North Carolina
United States Ellis Fischel Cancer Center at University of Missouri - Columbia Columbia Missouri
United States New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care Concord New Hampshire
United States CCOP - Hematology-Oncology Associates of Central New York East Syracuse New York
United States Elkhart Clinic, LLC Elkhart Indiana
United States Elkhart General Hospital Elkhart Indiana
United States Evanston Hospital Evanston Illinois
United States Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana
United States Wayne Memorial Hospital, Incorporated Goldsboro North Carolina
United States New Hampshire Oncology - Hematology, PA - Hooksett Hooksett New Hampshire
United States Holden Comprehensive Cancer Center at University of Iowa Iowa City Iowa
United States Kinston Medical Specialists Kinston North Carolina
United States Howard Community Hospital Kokomo Indiana
United States Center for Cancer Therapy at LaPorte Hospital and Health Services La Porte Indiana
United States Lakes Region General Hospital Laconia New Hampshire
United States Cancer Resource Center - Lincoln Lincoln Nebraska
United States Alegant Health Cancer Center at Bergan Mercy Medical Center Omaha Nebraska
United States CCOP - Missouri Valley Cancer Consortium Omaha Nebraska
United States Creighton University Medical Center Omaha Nebraska
United States Immanuel Medical Center Omaha Nebraska
United States Rex Cancer Center at Rex Hospital Raleigh North Carolina
United States Lakeside Cancer Specialists, PLLC Saint Joseph Michigan
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States Memorial Hospital of South Bend South Bend Indiana
United States Michiana Hematology-Oncology, PC - South Bend South Bend Indiana
United States Saint Joseph Regional Medical Center South Bend Indiana
United States South Bend Clinic South Bend Indiana
United States Lakeland Regional Cancer Care Center - St. Joseph St. Joseph Michigan
United States Iredell Memorial Hospital Statesville North Carolina
United States Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of patients who are progression-free at 12 weeks from the start of second-line therapy at 12 weeks No
Secondary Radiographic response rate Up to 2 years No
Secondary Overall survival Up to 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A